The Christ Hospital Health Network Becomes First in Four-State Region to Implant New Device for Aortic Valve Repair

The Christ Hospital Health Network is pleased to announce it has implanted the first JenaValve TAVR valve in the four-state region.

The Christ Hospital Health Network is pleased to announce it has implanted the first JenaValve TAVR valve in the four-state region. JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Pericardial transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, received “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA) in 2019. This designation is for severe aortic regurgitation (AR), a life-threatening and seriously debilitating condition, and AR-dominant mixed aortic valve disease in patients at high risk for surgery.

Aortic valve regurgitation occurs when the heart’s aortic valve does not close completely, allowing some of the blood pumped into the aorta to leak back into the left ventricle. With catheter-based systems like the Trilogy™ Valve, physicians can deliver a new heart valve through an artery in the leg, without open heart surgery, enabling the heart to pump normally once again.

In addition to being the first in the region, The Christ Hospital Health Network was also one of the first 15 centers in the country to implant the Trilogy™ Valve, a testament to the work of our heart and vascular physicians to pioneer cutting-edge treatments and devices. Minimally invasive technologies like the Trilogy™ Valve are crucial since many patients presenting with severe AR are not candidates for open-heart surgery because of various risks. Clinical research at The Christ Hospital offers a life-saving alternative for these patients.

“We offer a multitude of advanced life-saving treatments and medical devices at The Christ Hospital, many of which our physicians have helped to pioneer,” said Dean Kereiakes, MD, FACC, FSCAI, President of The Christ Hospital Heat and Vascular Institute. “I’m proud to say that The Christ Hospital was the first center in this region to implant the Trilogy™ Valve, continuing our tradition of transforming the heart and vascular landscape with new technologies, years before they become commercially available to other health care systems. This commitment to clinical research and advancements benefits not only patients in the Cincinnati region, but across the world.”

Currently, The Christ Hospital is the only center in the Cincinnati region with an American College of Cardiology-approved Valve Center of excellence, offering the most advanced treatments available regionally. Our team has extensive experience in diagnosing and treating aortic, mitral, pulmonary and tricuspid valve diseases, and is devoted to improving quality of life of our heart valve disease patients. For more information, please visit our heart valve disease page.

About The Christ Hospital Health Network The Christ Hospital Health Network is an acute care hospital locate in Mt. Auburn with a remote hospital location in Liberty Township, five ambulatory outpatient centers and dozens of offices conveniently located throughout the region. More than 1,300 talented physicians and more than 6,000 dedicated team members support the Network. Its mission is to improve the health of the community and to create patient value by providing exceptional outcomes and the finest experiences, all in an affordable way. The Network has been recognized by U.S. News & World Report as the #1 hospital in the Cincinnati Region and awarded Healthgrades “America’s 50 Best Hospitals” for being in the top 1% in the nation for providing the highest clinical quality year over year. It is also a Press Ganey Guardian of Excellence Award recipient, which recognizes top-performing healthcare organizations that achieve the 95th percentile or above of performance in patient experience. The Christ Hospital is among a select number of hospitals in the nation to be awarded Magnet® recognition for nursing excellence. For more than 130 years, The Christ Hospital has provided compassionate care to those it serves. About JenaValve Transfemoral TAVR System The JenaValve Trilogy™ Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol stent with a porcine pericardial tissue valve manufactured using state-of-the-art tissue processing techniques. The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters. The Trilogy™ Pericardial TAVR System is an investigational device and is not available for sale in the United States or internationally. About JenaValve JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K, and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. The Company is in clinical development of its next generation transfemoral TAVR system in both the U.S. and CE Mark countries for treating patients with aortic stenosis and/or aortic regurgitation. Additional information is available at www.jenavalve.com. ###